Alkaline-tolerant RNA aptamers useful to purify acid-sensitive antibodies in neutral conditions

Inomata, E.; Tashiro, Erika; Miyakawa, Shin; Nakamura, Yoshikazu; Akita, Kazumasa

doi:10.1016/j.biochi.2017.10.025

Cited by 12 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protein A and bevacizumab were used as the capture molecules in the strips. RNA aptamers that can specifically bind to the constant region of bevacizumab instead of protein A have been reported [16,17]. It may be possible to replace all capture molecules with DNA or RNA aptamers to improve the homogeneity and storage stability.…”

Section: Quantification Of Bevacizumab In Human Serum Samplesmentioning

confidence: 99%

Development of a Lateral Flow Assay for Bevacizumab Using an Anti-Idiotype DNA Aptamer as a Capture Molecule

et al. 2022

View full text Add to dashboard Cite

We developed a point-of-care testing method based on a lateral flow assay for bevacizumab, using an anti-idiotypic DNA aptamer as the capture molecule. Bevacizumab loaded onto the sample pad on the assay strip bound to the red-colored aptamer-modified gold nanoparticles (AuNPs) in the conjugation pad and then migrated into the developing zone. The AuNPs bound to bevacizumab were trapped by protein A on the test spot. In contrast, excess amounts of unreacted AuNPs on the control spot, confirming that they migrated correctly. The assay strips enabled analysis within 20 min after adding the sample, and bevacizumab was quantified by photographing the colored areas with a smartphone and analyzing the images. The assay kit was capable of quantifying bevacizumab in the range of 0-200 μg/mL in Avastin diluent and bevacizumab-spiked human serum samples. This assay method enables on-site analysis of bevacizumab concentrations with a simple operation and without special analytical apparatus.

show abstract

Section: Quantification Of Bevacizumab In Human Serum Samplesmentioning

confidence: 99%

Development of a Lateral Flow Assay for Bevacizumab Using an Anti-Idiotype DNA Aptamer as a Capture Molecule

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In many cases, aptamers are selected as DNA or RNA sequences and then modified post-selection. Commonly, DNA and RNA aptamers are converted to their 2′ modified counterparts, producing useful affinity reagents for applications that would be incompatible with natural nucleic acids (e.g., for stability in alkaline conditions) [194]. In many cases, such post-SELEX modifications decrease affinity of the original aptamer, arguing for direct selection in XNA systems where possible.…”

Section: Non-natural Nucleic Acids For Therapeutic Applicationsmentioning

confidence: 99%

Modified nucleic acids: replication, evolution, and next-generation therapeutics

2020

View full text Add to dashboard Cite

Modified nucleic acids, also called xeno nucleic acids (XNAs), offer a variety of advantages for biotechnological applications and address some of the limitations of first-generation nucleic acid therapeutics. Indeed, several therapeutics based on modified nucleic acids have recently been approved and many more are under clinical evaluation. XNAs can provide increased biostability and furthermore are now increasingly amenable to in vitro evolution, accelerating lead discovery. Here, we review the most recent discoveries in this dynamic field with a focus on progress in the enzymatic replication and functional exploration of XNAs.

show abstract

“…The aim of the Fc specific aptamers is to recognize epitopes which are commonly shared in the IgG domain of a certain species. These antibody binding aptamers are applicable for affinity chromatography [66], small protein detection [67], visualization of cells and organisms [68] and signal amplifiers [69][70][71], which would cause enhanced sensitivity and improved limit of detection and limit of quantitation.…”

Section: Fc Domain Specific Aptamersmentioning

confidence: 99%

“…Since the process is fully reversible and applied under neutral conditions, Apt8-2 seems to be an ideal recognition element in affinity chromatography ( Figure 4 A), i.e., as the elution step is very mild, unlike in case of using Protein A/G, the active conformation of the therapeutic antibodies can be maintained after purification/separation. Moreover, the Apt8-2 aptamer was further manipulated by ribose 2′-modification to generate Apt131, which was resistant in alkaline conditions (up to pH = 14), making the aptamer-modified resin reusable numerous times with equivalent binding capacity as Protein A [ 66 ]. The aptamers could also be used for oriented IgG immobilization in chemical sensors.…”

Section: Detection Of Iggs With Aptamersmentioning

confidence: 99%

See 1 more Smart Citation

Aptamers against Immunoglobulins: Design, Selection and Bioanalytical Applications

Bognár

Gyurcsányi

2020

IJMS

View full text Add to dashboard Cite

Nucleic acid aptamers show clear promise as diagnostic reagents, as highly specific strands were reported against a large variety of biomarkers. They have appealing benefits in terms of reproducible generation by chemical synthesis, controlled modification with labels and functionalities providing versatile means for detection and oriented immobilization, as along with high biochemical and temperature resistance. Aptamers against immunoglobulin targets—IgA, IgM, IgG and IgE—have a clear niche for diagnostic applications, therefore numerous aptamers have been selected and used in combination with a variety of detection techniques. The aim of this review is to overview and evaluate aptamers selected for the recognition of antibodies, in terms of their design, analytical properties and diagnostic applications. Aptamer candidates showed convincing performance among others to identify stress and upper respiratory tract infection through SIgA detection, for cancer cell recognition using membrane bound IgM, to detect and treat hemolytic transfusion reactions, autoimmune diseases with IgG and detection of IgE for allergy diseases. However, in general, their use still lags significantly behind what their claimed benefits and the plethora of application opportunities would forecast.

show abstract

Alkaline-tolerant RNA aptamers useful to purify acid-sensitive antibodies in neutral conditions

Cited by 12 publications

References 37 publications

Development of a Lateral Flow Assay for Bevacizumab Using an Anti-Idiotype DNA Aptamer as a Capture Molecule

Development of a Lateral Flow Assay for Bevacizumab Using an Anti-Idiotype DNA Aptamer as a Capture Molecule

Modified nucleic acids: replication, evolution, and next-generation therapeutics

Aptamers against Immunoglobulins: Design, Selection and Bioanalytical Applications

Contact Info

Product

Resources

About